# Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

> **NCT00710372** · PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG** · enrollment: 83 (actual)

## Conditions studied

- Mild Essential Hypertension
- Moderate Essential Hypertension

## Interventions

- **BIOLOGICAL:** CYT006-AngQb

## Key facts

- **NCT ID:** NCT00710372
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-07
- **Final completion:** 2010-11
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2010-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710372, "Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00710372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*